Ownership and insider activity for OmniAb, Inc. (OABI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments.
Price
| Price | $4.35 |
| Market Cap | $631M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 0 | 0 | $33.4M | $16.4M | $27.6M | $25.5M |
| Short-term Investments | 0 | 0 | 0 | $54.9M | $70.6M | $31.8M | $28.5M |
| Receivables | $7.8M | $15.9M | $21.1M | $30.3M | $3.8M | $5.3M | $7.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $7.8M | $16.6M | $22.5M | $125.0M | $94.9M | $68.1M | $65.3M |
| Property, Plant & Equipment | $4.3M | $6.0M | $20.1M | $41.5M | $38.1M | $33.3M | $25.0M |
| Goodwill | $77.1M | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M |
| Intangible Assets | $173.0M | $186.6M | $176.3M | $167.2M | $155.5M | $138.1M | $125.1M |
| Total Assets | $262.3M | $295.4M | $304.5M | $421.2M | $375.2M | $325.6M | $300.9M |
| Accounts Payable | $806000 | $469000 | $2.9M | $3.0M | $4.4M | $2.3M | $1.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.1M | $14.3M | $20.6M | $26.0M | $23.1M | $15.1M | $16.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $44.1M | $59.8M | $70.2M | $79.8M | $60.6M | $37.9M | $33.9M |
| Retained Earnings | 0 | 0 | 0 | $11.3M | -$39.4M | -$101.4M | -$166.2M |
| Total Equity | $218.2M | $235.5M | $234.3M | $341.4M | $314.6M | $287.6M | $267.0M |
| Total Debt | $2.6M | $2.6M | $13.8M | $25.8M | $25.6M | $23.2M | $20.3M |
| Net Debt | $2.6M | $2.6M | $13.8M | -$62.5M | -$61.4M | -$36.3M | -$33.7M |
| Working Capital | $1.7M | $2.4M | $2.0M | $98.9M | $71.8M | $53.0M | $49.1M |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 4.80 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 2.42 |
Profitability
| Return on Equity | -16.59% |
| Return on Invested Capital | -17.24% |
| Return on Assets | -15.25% |
| Gross Margin | 50.53% |
| Operating Margin | -125.79% |
| Net Margin | -115.18% |
Related companies: ARMP · CCCC · CDXS · IMDX · IPHA · IVVD · MIST
Explore sector: Healthcare · Biotechnology
More sections of OABI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks